人乳头瘤病毒疫苗接种的人群层面影响、群体免疫与消除:传播动态模型预测的系统综述与Meta分析
该系统综述与Meta分析检索了2009年1月1日至2015年4月28日MEDLINE和Embase中高收入国家HPV 6/11/16/18传播动态模型研究,16个模型提供了标准化情景预测。结果显示仅接种女孩即可产生强群体效应,男女均接种且覆盖率达80%时多数模型预测可消除HPV 6/11/16/18。
要点
- 仅接种女孩在40%覆盖率下,女性HPV 16相对患病率降至0.53(80% UI 0.46-0.68)。
- 男女均接种较仅女孩接种在80%覆盖率下对女性HPV 16的额外相对下降为0.07(80% UI 0.00-0.10)。
- 80%覆盖率下男女均接种,多数模型预测可消除HPV 6/11/16/18(中位RRprev 1.00)。
核心结论
- 尽管HPV模型在结构、校准数据和设置上存在差异,人群层面预测总体一致,提示仅接种女孩即可产生强群体效应,即使覆盖率低至20%。
- 若女孩和男孩接种覆盖率达到80%且高疫苗效力随时间维持,消除HPV 16、18、6和11是可能的。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE和Embase中2009年1月1日至2015年4月28日发表的传播动态模型研究。
- 纳入预测高收入国家HPV 6、11、16和18感染人群层面影响的模型,19个合格模型中的16个提供了预测。
- 研究情景为12岁女孩仅接种和女孩加男孩接种,基线疫苗特征为100%效力和终身保护,并做敏感性分析。
主要发现
- 基线假设下40%覆盖率仅女孩接种,70年后女性HPV 16的RRprev为0.53(80% UI 0.46-0.68),男性为0.36(80% UI 0.28-0.61)。
- 80%覆盖率仅女孩接种,女性HPV 16的RRprev为0.93(80% UI 0.90-1.00),男性为0.83(80% UI 0.75-1.00)。
- 40%覆盖率下增加男孩接种使女性HPV 16的RRprev增加0.18(80% UI 0.13-0.32),男性增加0.35(80% UI 0.27-0.39)。
- 80%覆盖率下增加男孩接种使女性HPV 16的RRprev增加0.07(80% UI 0.00-0.10),男性增加0.16(80% UI 0.01-0.25)。
- 所有情景下HPV 6、11和18的RRprev均大于HPV 16;80%覆盖率下男女均接种,多数模型预测可消除四种HPV型别,女性和男性中位RRprev均为1.00。
关键数值与推荐
- 相对患病率降低(RRprev)采用中位数和10th-90th百分位数(80%不确定性区间[UI])汇总。
- 基线疫苗特征为100%效力和终身保护,敏感性分析改变接种覆盖率、疫苗效力和保护持续时间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 汇总结果的变异性低,但在较低接种覆盖率和较短疫苗保护(从终身到20年)时变异性增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Modelling studies have been widely used to inform human papillomavirus (HPV) vaccination policy decisions; however, many models exist and it is not known whether they produce consistent predictions of population-level effectiveness and herd effects. We did a systematic review and meta-analysis of model predictions of the long-term population-level effectiveness of vaccination against HPV 16, 18, 6, and 11 infection in women and men, to examine the variability in predicted herd effects, incremental benefit of vaccinating boys, and potential for HPV-vaccine-type elimination. METHODS: We searched MEDLINE and Embase for transmission-dynamic modelling studies published between Jan 1, 2009, and April 28, 2015, that predicted the population-level impact of vaccination on HPV 6, 11, 16, and 18 infections in high-income countries. We contacted authors to determine whether they were willing to produce new predictions for standardised scenarios. Strategies investigated were girls-only vaccination and girls and boys vaccination at age 12 years. Base-case vaccine characteristics were 100% efficacy and lifetime protection. We did sensitivity analyses by varying vaccination coverage, vaccine efficacy, and duration of protection. For all scenarios we pooled model predictions of relative reductions in HPV prevalence (RRprev) over time after vaccination and summarised results using the median and 10th and 90th percentiles (80% uncertainty intervals [UI]). FINDINGS: 16 of 19 eligible models from ten high-income countries provided predictions. Under base-case assumptions, 40% vaccination coverage and girls-only vaccination, the RRprev of HPV 16 among women and men was 0·53 (80% UI 0·46-0·68) and 0·36 (0·28-0·61), respectively, after 70 years. With 80% girls-only vaccination coverage, the RRprev of HPV 16 among women and men was 0·93 (0·90-1·00) and 0·83 (0·75-1·00), respectively. Vaccinating boys in addition to girls increased the RRprev of HPV 16 among women and men by 0·18 (0·13-0·32) and 0·35 (0·27-0·39) for 40% coverage, and 0·07 (0·00-0·10) and 0·16 (0·01-0·25) for 80% coverage, respectively. The RRprev were greater for HPV 6, 11, and 18 than for HPV 16 for all scenarios investigated. Finally at 80% coverage, most models predicted that girls and boys vaccination would eliminate HPV 6, 11, 16, and 18, with a median RRprev of 1·00 for women and men for all four HPV types. Variability in pooled findings was low, but increased with lower vaccination coverage and shorter vaccine protection (from lifetime to 20 years). INTERPRETATION: Although HPV models differ in structure, data used for calibration, and settings, our population-level predictions were generally concordant and suggest that strong herd effects are expected from vaccinating girls only, even with coverage as low as 20%. Elimination of HPV 16, 18, 6, and 11 is possible if 80% coverage in girls and boys is reached and if high vaccine efficacy is maintained over time. FUNDING: Canadian Institutes of Health Research.
引用
- Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016. PMID: 29253379. doi:10.1016/S2468-2667(16)30001-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。